February 2017 in “대한피부과학회지” Combining low-dose dutasteride with finasteride improved a man's hair loss.
Neurosteroids help control dopamine responses in the brain.
August 2024 in “Research Square (Research Square)” Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
November 2023 in “Expert Opinion on Pharmacotherapy” Finasteride and dutasteride are effective in treating male hair loss but can cause sexual side effects and birth defects.
March 2026 in “The Aging Male” PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
December 2025 in “International Neurourology Journal” Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.
December 2025 in “Cureus” Using 5α-reductase inhibitors for hair loss may increase the risk of dry eye disease.
September 2025 in “Journal of Natural Remedies” Herbal drugs show promise for treating alopecia with fewer side effects, but standardization is challenging.
September 2025 in “JAAD reviews.” Finasteride and dutasteride can improve hair loss in women, but more research is needed.
September 2025 in “Journal of the American Academy of Dermatology” Using 5α-reductase inhibitors for hair loss in women doesn't increase cancer risk.
September 2024 in “Frontiers in Neuroendocrinology” 5-alpha reductase inhibitors may help protect the brain and gut in Parkinson's disease.
July 2024 in “Actas Dermo-Sifiliográficas” Finasteride and dutasteride do not significantly change beard thickness in men.
July 2024 in “Journal of Investigative Dermatology” 5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
July 2024 in “Age and Ageing” Men taking dutasteride may have a higher risk of age-related macular degeneration.
May 2024 in “Scientific African” Three natural compounds from Ghanaian plants may help treat BPH and alopecia.
April 2024 in “The Journal of urology/The journal of urology” 5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.
July 2023 in “Dermatology and Therapy” 5-Alpha Reductase Inhibitors are effective for male hair loss and some skin conditions, but their effectiveness in women and safety concerns require careful use.
June 2023 in “Research Square (Research Square)” A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.
Canadian lawsuits involving 5-alpha-reductase inhibitors are related to persistent erectile dysfunction side effects, with no judgments against companies yet.
January 2021 in “Journal of the European Academy of Dermatology and Venereology” PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
January 2019 in “Nihon Yakuri Gakkai nenkai yoshishu” Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.
April 2017 in “The Journal of urology/The journal of urology” 5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
January 2016 in “Archivio italiano di urologia, andrologia” The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.
March 2014 in “The Journal of Urology” Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.
December 2012 in “Canadian Urological Association Journal” 5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.
November 2011 in “Nature Clinical Practice Urology” 5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.
October 2008 in “The Journal of Urology” Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.